PRNewsWire
05 Jan 2026, 15:30 UTC · 36w ago
Verdict
Headline leans bearish. We score CTOR −0.80 across one claim.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Purcell & Lefkowitz LLP is investigating Citius Oncology, Inc. (NASDAQ: CTOR) to determine whether its directors breached their fiduciary duties in connection with recent corporate actions.
More negative than 96% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More negative than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 87% of ticker scores this week
The company is under investigation for potential breaches of fiduciary duties by its directors.
More negative than 87% of ticker scores this week
The company is the subject of a shareholder investigation regarding corporate misconduct.
More negative than 87% of ticker scores this week
The company is being investigated on behalf of its shareholders by a law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1d ago
−18.8%
Price agrees with the score
$0.8774 vs $1.08 close before publication (Jan 2) · not market-adjusted
CTOR chart →
